Aflibercept (Eylea) in roUtine clinical practice in patientS with wet age-related macular degeneration in Italy (PERSEUS–IT)
The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in routine clinical practice in Italy for a study population of “naïve” patients
- “Naïve” patients with wet AMD(age-related macular degeneration) treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).
- Exclusion criteria as listed in the local SPC. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye. - Any concomitant therapy with another agent to treat wet AMD in the study eye. - Any prior or concomitant therapy with another drug for wAMD.
Many Locations, Italy
E-mail: [email protected]
Phone: (+) 1-888-8422937
PERSEUS-IT. A Prospective non-intERventional study to asSEss the effectiveness of Aflibercept (Eylea®) in roUtine clinical practice in patientS with wet age-related macular degeneration in Italy